United States Patent 10,695,345: What Is Claimed, How Broad the Coverage Is, and Where It Sits in the US Lumateperone Capsule Landscape
US Patent 10,695,345 claims a specific oral hard-gelatin capsule formulation of lumateperone in mono-tosylate salt form, where the salt is required to be in a defined solid crystalline state, combined with a defined quantitative excipient blend, plus optional limitations around capsule type, colorants, particle attributes, crystallinity by XRPD, dissolution, manufacturing steps, and in-vivo exposure.
Below is a structured breakdown of claim scope, coverage boundaries, likely infringement-adjudication issues, and what the claim set implies for the broader US patent landscape for lumateperone solid oral dosing.
What Is the Core Invention Claiming? (Independent Claim 1)
Claim 1 defines an oral pharmaceutical capsule comprising:
- Active: lumateperone mono-tosylate
- salt form: mono-tosylate
- state: solid crystal form
- Dose blend (by weight):
- 10 to 30% by weight lumateperone mono-tosylate (solid crystal)
- 60 to 90% by weight mannitol
- 0.5 to 10% by weight croscarmellose sodium
- 0.1 to 1% by weight talc
- 0.1 to 3% by weight magnesium stearate
- Dosage form container: filled into a gelatin capsule
That combination is the center of gravity: if a product differs in salt identity, crystal state, or the excipient ratio ranges, it can escape claim 1 even if it uses “lumateperone tosylate” broadly.
How Much Extra Scope Do the Dependent Claims Add? (Claims 2-18)
Capsule configuration limitations
- Claim 2: the gelatin capsule is size 0
- Claim 3: size 0 capsule includes one or more colorants from:
- FD&C Yellow #6, FD&C Blue #1, FD&C Red #3
- black iron oxide, red iron oxide
- titanium dioxide
- or combinations
- Claim 11: capsule is hard-shelled
Coverage impact: size 0 and colorants are narrower features; a generic that uses a different capsule size and omits colorants can still fall within claim 1 but avoid claims 2-3.
Dose amount equivalents (translating salt weight to free base)
- Claim 4: lumateperone mono-tosylate amount is equivalent to 35 to 45 mg lumateperone free base
- Claim 5: equivalent to about 42 mg free base
- Claim 6: capsule contains about 60 mg lumateperone mono-tosylate
- Claim 7: a refined “blend” range version with:
- about 60 mg lumateperone mono-tosylate (solid crystal)
- 70 to 80% mannitol
- 0.5 to 5% croscarmellose sodium
- 0.1 to 1% talc
- 0.1 to 1% magnesium stearate
- Claim 9: similar to claim 7 but adds optional colorants and fixes:
- about 60 mg lumateperone mono-tosylate
- 70 to 80% mannitol
- 0.5 to 5% croscarmellose sodium
- 0.1 to 1% talc
- 0.1 to 1% magnesium stearate
- Claim 10: an explicit quantitative example:
- about 60 mg lumateperone mono-tosylate (solid crystal)
- about 221 mg mannitol
- about 15 mg croscarmellose sodium
- about 0.9 mg talc
- about 3 mg magnesium stearate
- plus optional colorants
Coverage impact: claims 4-6 and 7-10 tie directly to the commonly targeted dose regime (42 mg free base corresponds to a defined salt amount). A product using a different dose strength or different salt loading can avoid most dependent claims while still potentially intersecting claim 1.
Crystallinity by XRPD (strongest technical discriminator)
- Claim 8: the lumateperone mono-tosylate solid crystal exhibits an XRPD pattern with at least two peaks at specified 2-theta values (±0.2°):
- 5.68°, 12.11°, 16.04°, 17.03°, 18.16°, 19.00°, 21.67°, 22.55°, 23.48°, 24.30°
Coverage impact: This is often where infringement lives or dies. If a competitor uses a different polymorph/solvate/anhydrate form, or even a different crystalline habit that shifts peaks beyond ±0.2°, they can avoid claim 8 while still possibly meeting the broader “solid crystal form” language in claim 1. But in disputes, claim charts often treat XRPD as the practical proof threshold.
Particle size limits (solid-state processing discriminator)
- Claim 12: lumateperone present with specified particle attributes:
- mean particle size 1 to 200 μm
- and/or D90 ≤ 100 μm
- and/or D10 ≤ 50 μm
- optionally narrower:
- D90 ≤ 10 μm
- D10 ≤ 5 μm
- PSD D50 2 to 5 μm
- Claim 15: narrows claim 12 to:
- mean particle size 1 to 5 μm
- and/or D90 ≤ 10 μm
- and/or D10 ≤ 5 μm
- Claim 16: narrows further to:
- D90 ≤ 10 μm
- D10 ≤ 5 μm
- and/or PSD D50 2 to 5 μm
Coverage impact: particle size is a common generics battle point (milling, jet milling, sieving, PSD characterization). But claim 12 is broad enough that many comminuted solids can fall inside; narrower claims 15-16 are easier to design around by accepting larger particle distributions.
Dissolution requirements (in vitro functional discriminator)
- Claim 17: a single capsule dissolves in 500 mL of 0.1N aqueous hydrochloric acid to at least:
- 85% after 15 minutes
- 92% after 30 minutes
- 94% after 45 minutes
Coverage impact: Functional limits drive testing-based infringement arguments and can require choosing similar excipient system and/or manufacturing process to hit dissolution.
Pharmacokinetics / exposure targets (in vivo functional discriminator)
- Claim 18: under fasting conditions, oral dose from a single capsule with 60 mg lumateperone tosylate yields:
- Cmax: 15 to 55 ng/mL, mean Cmax 30 to 40 ng/mL
- Tmax: 0.7 to 1.5 hours, mean Tmax 1 to 1.2 hours, median about 1 hour
- AUC extrapolated to infinity:
- 51 to 135 hr·ng/mL
- mean 70 to 115 hr·ng/mL
- or 85 to 100 hr·ng/mL
Coverage impact: This type of claim is enforceable, but often hinges on test evidence, trial design similarity, and whether an accused product reproduces the exposure window rather than just being bioequivalent in the regulatory sense.
What Is Claimed Beyond the Formulation? (Process and Use Claims)
Manufacturing process
- Claim 13: process comprises:
- combine lumateperone mono-tosylate solid crystal with a portion of mannitol
- blend
- optionally filter
- add additional mannitol, croscarmellose sodium, talc, magnesium stearate
- blend
- optionally filter
- encapsulate into gelatin capsule
- optionally apply capsule coatings
Coverage impact: Process claims are sometimes narrower because accused manufacturers may use different order-of-addition or equipment; but if the process structure is followed, a claim can still be asserted.
Therapeutic use
- Claim 14: method of treatment/prophylaxis of disease mediated by 5-HT2A receptor, SERT, and/or dopamine D1/D2 signaling, where the disease is schizophrenia.
Coverage impact: A use claim can support infringement even when formulation choices differ, but only if claim 1 formulation is still met because claim 14 depends on claim 1 (“administering the capsule according to claim 1”).
Where Does This Land in the US Patent Landscape? (Practical Battlefield Read-Out)
This patent is not a “mere” lumateperone composition claim
It is a crystal-defined, capsule-filled, excipient-range claim. In US litigation terms, that is a high specificity profile that typically narrows the set of structurally equivalent designs and pulls the dispute into:
- salt/crystal characterization (XRPD peak set and crystal identity)
- dose formulation matching (salt loading and excipient percentages)
- solid-state processing (particle size PSD)
- dissolution performance (in 0.1N HCl)
- human exposure outcomes (Cmax/AUC/Tmax ranges)
Key implication for competitor design-around
The easiest points to test and alter without changing the therapeutic compound are:
- crystal form identity (while keeping “solid”)
- XRPD peak matching (to defeat claim 8)
- excipient ratio ranges (to defeat claim 1)
- particle size PSD targets (to defeat claims 12, 15, 16)
- dissolution curve (to defeat claim 17)
- capsule size and colorants (to defeat claims 2-3)
- PK window is harder but may still be missed by formulation changes (claims 18)
Claim Scope Matrix (How Broad vs. Narrow the Coverage Is)
| Claim element |
Included limits |
Breadth |
Likely design-around lever |
| Salt identity and state |
lumateperone mono-tosylate; “solid crystal form” |
Medium |
Use different solid form; different salt form |
| XRPD crystallinity |
specified peaks (2-theta values ±0.2°) |
Narrow |
Choose a different polymorph or crystalline form |
| Excipient ranges (core) |
10-30% active; 60-90% mannitol; 0.5-10% CCS; 0.1-1% talc; 0.1-3% MgSt |
Medium |
Rebalance ratios outside at least one range |
| Dose amount (dependent) |
equivalents to 35-45 mg free base; about 60 mg salt |
Medium |
Change strength or salt loading |
| Capsule size and colorants |
size 0; FD&C and pigment list |
Narrow |
Use different capsule size or omit colorants |
| Particle size |
D90, D10, mean; optional narrower PSD |
Medium to Narrow |
Change milling and PSD |
| Dissolution |
percent dissolution in 0.1N HCl at 15/30/45 min |
Narrow |
Formulation/process to shift dissolution |
| PK window |
Cmax/Tmax/AUC target ranges fasting |
Narrow |
Formulation changes that shift exposure characteristics |
| Process |
order-of-addition and blending steps; optional filtering/coating |
Medium |
Use different manufacturing sequence/equipment |
Infringement Proof Targets (What Typically Has to Be Shown)
For claim 1 (main target)
A plaintiff typically needs to demonstrate all of:
- The accused product uses lumateperone mono-tosylate (not another lumateperone salt)
- The mono-tosylate is in a solid crystalline form
- The capsule blend matches the weight percentage ranges across the excipients
- The capsule is gelatin capsule filled
For claim 8 (XRPD)
Plaintiff needs a crystallinity showing at least two peaks at listed 2-theta values within ±0.2°.
For claim 17 (dissolution)
Plaintiff needs dissolution testing that reproduces the “single capsule” test in 500 mL 0.1N HCl with the stated time points.
For claim 18 (PK)
Plaintiff needs fasting-condition human exposure evidence consistent with the defined Cmax/Tmax/AUC windows.
For dependent capsule configuration claims (2-3, 11)
Plaintiff needs physical attributes of the capsule shell and presence/absence of listed colorants.
Strategic Reading: What the Claim Set Suggests About Market Positioning
The claim set is built around a very specific oral solid dose product profile:
- A defined crystal-state mono-tosylate salt
- Capsule filled with a typical directly-compressible excipient backbone using mannitol plus superdisintegrant (croscarmellose), lubricant (magnesium stearate), and flow/processing aid (talc)
- Performance tied to dissolution and exposure, not just composition
This kind of claim package is typically aimed at blocking “close” formulations that:
- match the active salt concept but swap solid form
- keep similar excipient backbone but shift the ratios outside range
- use different PSD and manufacturing milling approaches
- produce similar bioavailability but not within the stated PK windows
Key Takeaways
- Independent claim 1 controls the broadest coverage: lumateperone mono-tosylate in solid crystal form at 10-30% by weight, with defined excipient percentage ranges, in a gelatin capsule.
- The strongest technical discriminator is claim 8 (XRPD peak set) with specified 2-theta values ±0.2°, which is a common failure point for “form-switching” competitors.
- The next most decisive discriminators are dose-equivalent loading (claims 4-6, 7-10), particle size PSD (claims 12, 15, 16), and functional performance (dissolution in 0.1N HCl in claim 17).
- Claim 18 adds a high-evidentiary bar by anchoring infringement to fasted PK ranges after a single capsule containing 60 mg lumateperone tosylate.
- Capsule size 0 and listed colorants in claims 2-3 are narrow add-ons; they matter for fallback positions but are not required for claim 1.
FAQs
1) Does US 10,695,345 cover any lumateperone oral capsule?
No. It covers capsules that use lumateperone mono-tosylate in solid crystal form with excipients in the specified weight ranges in claim 1, and those limitations flow into dependent claims.
2) What is the most likely design-around point for a competitor?
XRPD/crystal identity under claim 8 and excipient ratio ranges under claim 1. Changing solid form or shifting weight percentages can move the product out of claim coverage.
3) Are particle size and dissolution required for all coverage?
Particle size and dissolution are in dependent claims (claims 12-17). Claim 1 alone does not require the specific particle size or dissolution thresholds, but they matter for those narrower claims.
4) Is the PK claim (claim 18) enforceable like a composition claim?
It is an additional dependent limitation tied to fasted exposure parameters. Enforcement generally relies on human study evidence showing the accused product matches the stated Cmax/Tmax/AUC ranges.
5) Can a product avoid the patent by using a different capsule size?
It can avoid claims 2-3 if it uses a capsule size other than size 0 or omits listed colorants. But it does not automatically avoid claim 1, which does not require size 0.
References
[1] US Patent 10,695,345 (claim set provided in prompt).
